FOLFIRINOX and the combination of gemcitabine plus nab-paclitaxel (Abraxane) have demonstrated survival advantages in the first-line setting for patients with metastatic pancreatic cancer, says Ocean. However, these patients often progress and require second-line therapy. Read more . . .
Allyson Ocean, MD, an associate attending physician, NewYork-Presbyterian Hospital, and associate professor of clinical medicine at Weill Cornell Medicine, discusses the need for additional second-line therapies in metastatic pancreatic cancer.